NCT01582243View on ClinicalTrials.gov

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)

Trial Locations (1)

500

Novartis Investigative Site, Changhua

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY